---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002313"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:40:31.038116+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kala Bio targeting CHASE Phase 2b data for KPI-012 (PCED) by end of 2024

## Summary
- Topline safety and efficacy data from CHASE Phase 2b trial expected by year-end 2024.
- KPI-012 is a human mesenchymal stem cell secretome for persistent corneal epithelial defect.
- Corporate presentation posted on investors section of company website; no other material updates.
- No financial guidance or operational changes disclosed in this filing.

## SEC filing metadata
- accession: 0001558370-24-002313
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024002313/0001558370-24-002313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024002313/kala-20240304x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002313
- JSON: https://secwatch.observer/filing/0001558370-24-002313.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002313.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.